Expression of the Epstein‐Barr virus BHRF1 gene, a homologue of Bcl‐2, in nasopharyngeal carcinoma tissue

Epstein‐Barr virus (EBV) infection is associated closely with the pathogenesis of nasopharyngeal carcinoma (NPC). The EBV gene product, BHRF1, has been demonstrated in vitro and is structurally and functionally similar to the oncogene bcl‐2, that is able to protect cells from programmed cell death. To determine whether the BHRF1 gene is expressed in vivo, BHRF1 mRNA or protein were sought in tissues from NPC and non‐NPC patients. BHRF1 transcripts were specifically detected in the NPC tumours (32 out of 44, 72.7%) rather than the non‐NPC tissues (0 out of 25) by reverse transcription, polymerase chain reaction and Southern hybridization. Other EBV genes, such as the lytic gene BZLF1 and latent genes EBNA1 and LMP2A, were also investigated. BZLF1 transcripts also were found specifically in NPC tumours (33 out of 44, 75%). EBNA1 was expressed in 79.5% of NPC, and 28% of non‐ NPC, tissues and LMP2A was expressed in 70.5% of NPC, and 88% of non‐NPC, tissues. BHRF1 protein was detected by immunohistochemistry in 4 metastatic NPC, of 36 NPC tissue sections available. The BHRF1 protein was distributed in both the nucleus and cytoplasm of the neoplastic epithelial cells. IgG antibody against the BHRF1 protein was detected in 6 of 17 (35.3%) NPC plasma, but the protein and IgG were both absent from the non‐NPC controls. BHRF1 DNA sequences were determined for 11 NPC and 3 non‐NPC samples. No sequence was specific for the EBV isolates from NPC tissue. Amino acids 79 and 88 always appeared in the same form, however, for every tested isolate and both were valine or leucine. This particular characteristic was not present in the B95‐8 strain or in the corresponding regions of homologues, Bcl‐2 and Bcl‐Xl, and was regarded as unique to Oriental EBV strains. J. Med. Virol. 61:241–250, 2000. © 2000 Wiley‐Liss, Inc.

[1]  Chien-Jen Chen,et al.  Antibody against the Epstein‐Barr virus BHRF1 protein, a homologue of Bcl‐2, in patients with nasopharyngeal carcinoma , 1998, Journal of medical virology.

[2]  L. Young,et al.  Functional Differences between BHRF1, the Epstein-Barr Virus-Encoded Bcl-2 Homologue, and Bcl-2 in Human Epithelial Cells , 1998, Journal of Virology.

[3]  L. Yu,et al.  Epstein-Barr virus BHRF1 prohibits the cells of nasopharyngeal carcinoma from apoptosis , 1997, The Journal of Laryngology & Otology.

[4]  F. Khanim,et al.  BHRF1, a viral homologue of the Bcl-2 oncogene, is conserved at both the sequence and functional level in different Epstein-Barr virus isolates. , 1997, The Journal of general virology.

[5]  C. J. Chen,et al.  Evaluation of multiple antibodies to Epstein‐Barr virus as markers for detecting patients with nasopharyngeal carcinoma , 1997, Journal of medical virology.

[6]  M. Kawanishi,et al.  Epstein-Barr virus BHRF1 protein protects intestine 407 epithelial cells from apoptosis induced by tumor necrosis factor alpha and anti-Fas antibody , 1997, Journal of virology.

[7]  G. Srivastava,et al.  Nasal NK‐ and T‐cell lymphomas share the same type of Epstein‐Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease , 1996, International journal of cancer.

[8]  F. Berger,et al.  Expression of the DNase encoded by the BGLF5 gene of Epstein-Barr virus in nasopharyngeal carcinoma epithelial cells. , 1996, Virology.

[9]  H. Takeuchi,et al.  Detection of latent infection by Epstein-Barr virus in peripheral blood cells of healthy individuals and in non-neoplastic tonsillar tissue from patients by reverse transcription-polymerase chain reaction. , 1996, Journal of virological methods.

[10]  G. Chinnadurai,et al.  Unmasking of a proliferation-restraining activity of the anti-apoptosis protein EBV BHRF1. , 1996, Oncogene.

[11]  C. Meijer,et al.  Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. , 1995, The American journal of pathology.

[12]  D. Martel-Renoir,et al.  Qualitative analysis of the expression of Epstein-Barr virus lytic genes in nasopharyngeal carcinoma biopsies. , 1995, The Journal of general virology.

[13]  G. Evan,et al.  Induction of apoptosis by the Bcl-2 homologue Bak , 1995, Nature.

[14]  P. Farrell,et al.  Novel hypotheses for the roles of EBNA-1 and BHRF1 in EBV-related cancers. , 1995, Intervirology.

[15]  G. Winberg,et al.  Coupled transcription of Epstein-Barr virus latent membrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas. , 1995, The Journal of general virology.

[16]  L. Young,et al.  Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state , 1994, Journal of virology.

[17]  P. Swanson Microwave Antigen Retrieval in Citrate Buffer , 1994 .

[18]  U. Prasad,et al.  Analysis of epstein‐barr virus infection in nasopharyngeal biopsies from a group at high risk of nasopharyngeal carcinoma , 2009, International journal of cancer.

[19]  D. Martel-Renoir,et al.  Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. , 1993, Virology.

[20]  E. Kieff,et al.  Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[22]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[23]  E. Kieff,et al.  Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation , 1993, Journal of virology.

[24]  G. Elia,et al.  Bcl‐2 proto‐oncogene expression in epstein‐barr‐virus‐associated nasopharyngeal carcinoma , 1993, International journal of cancer.

[25]  D. Rowe,et al.  Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes , 1992, Journal of virology.

[26]  Q Y Yao,et al.  Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts , 1992, Journal of virology.

[27]  T. Tursz,et al.  Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma , 1992, Journal of virology.

[28]  U. Prasad,et al.  Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. , 1992, The American journal of pathology.

[29]  J. Epstein,et al.  Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. , 1991, The American journal of pathology.

[30]  E. Kieff,et al.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Shu,et al.  Epstein-Barr virus small RNA (EBER) genes: Unique transcription units that combine RNA polymerase II and III promoter elements , 1989, Cell.

[32]  Chien-Jen Chen,et al.  Antibody to Epstein‐Barr virus‐specific DNase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan , 1989, Journal of medical virology.

[33]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[34]  Pierre Busson,et al.  Expression of Epstein‐Barr virus‐encoded proteins in nasopharyngeal carcinoma , 1988, International journal of cancer.

[35]  T. Tursz,et al.  Epstein-Barr virus gene expression in nasopharyngeal carcinoma. , 1988, The Journal of general virology.

[36]  E. Kieff,et al.  Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. , 1987, Virology.

[37]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[38]  C. J. Chen,et al.  Antibody to Epstein‐Barr virus‐specific DNase as a marker for the early detection of nasopharyngeal carcinoma , 1985, Journal of medical virology.

[39]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[40]  W. Henle,et al.  Epstein‐barr virus‐specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma , 1976, International journal of cancer.

[41]  E. Southern Detection of specific sequences among DNA fragments separated by gel electrophoresis. , 1975, Journal of molecular biology.

[42]  G. Klein,et al.  Establishment and characterization of an Epstein-Barr virus (EBC)-negative lymphoblastoid B cell line (BJA-B) from an exceptional, EBV-genome-negative African Burkitt's lymphoma. , 1975, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

[43]  H. Hausen,et al.  EB viral genomes in epithelial nasopharyngeal carcinoma cells. , 1973, Nature: New biology.

[44]  V. Diehl,et al.  Occurrence of Epstein-Barr virus genomes in human lymphoblastoid cell lines. , 1972, Nature: New biology.

[45]  G. Miller,et al.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[46]  V. Diehl,et al.  Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. , 1970, Journal of the National Cancer Institute.

[47]  Y. Hinuma,et al.  Cloning of Immunoglobulin-Producing Human Leukemic and Lymphoma Cells in Long-Term Cultures.∗ , 1967, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[48]  R. Pulvertaft A study of malignant tumours in Nigeria by short-term tissue culture , 1965, Journal of clinical pathology.